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424 LETTERS TO THE EDITOR2. The authors implied isolation of Rhodococcus from cul-
ture media, but they initiated empirical therapy without
performing antimicrobial drug susceptibility test. The
antibiogram test is necessary for appropriate treatment
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report “Rhodococcus equi Pneumonia in a Kidney
Transplant Recipient Affected by Acute Intermittent
Porphyria” [1].A S precisely reported by the authors, Rhodococcus equiis Gram-positive, occasionally acid-fast, bacterium
living in soil water, decaying plant and stool of herbivores
[2]. In humans, Rhodococcus equi causes opportunistic in-
fections occurring principally in immunosuppressed pa-
tients, including solid organ and hematopoietic stem cell
recipients and people living with human immunodeficiency
virus. Given that Rhodococcus equi is widely present in the
environment, impairment of the immune response rather
than exposure to the pathogen has been considered the
main predisposing factor for the development of this
infection.
Rhodococcus equi infection frequently involves lung pa-
renchyma and manifests with pneumonia, high fever, fatigue
and chest pain. Extrapulmonary organ involvement occurs
only in 25% of cases [3].
In the last decades, ameliorations of the laboratory tech-
niques for the identification of Rhodococcus species has
increased the rate of recognition of this bacterium. The path-
ogen is commonly detected from biological specimens such as
sputum, bronchoalveolar lavage fluid, pleural fluid, abscess
aspirate, peritoneal fluid, cerebrospinal fluid, lymph nodes,
and tissue culture from any suspected affected organ. Positive
blood culture is seen only in patients with hematogenous
spread of lung infection [2].
Rhodococcus equi regularly grows on enriched media
including blood and chocolate agar. On Sabouraud agar
and purple lactose agar, the colonies turn salmon-pink due
to the production of a characteristic substance. Rhodo-
coccus equi is a facultative intracellular pathogen that re-
sides in macrophages and causes granulomatous
inflammation. It is a slow-growing bacterium without he-
molytic activity when cultured in blood agar. Its shape
changes from coccoid form in solid media to long curved
clubbed form in liquid media.
In our laboratory, Rhodococcus equi grew on sheep blood
and chocolate agar after 7 days of incubation. Identification of
the Rhodococcus species occurred by the structural charac-
terization of mycolic acids through mass spectrometry [4].
According to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) guidelines [5], the path-
ogen was susceptible to levofloxacin (minimal inhibitory
concentration [MIC] of 1 MIC mg/L). MIC testing was also
performed for erythromycin, vancomycin, and teicoplanin
(MIC of 12, 0.38, and 0.50, respectively), but antimicrobic
sensitivity was not furnished because EUCAST did not
recommend any interpretive breakpoints. Our choice to treat
Rhodococcus equi infection with azithromycin and mer-
openemwas based both on the ability of azithromycin to have
intracellular penetration and the documented in-vitro activity
ofmeropenemagainstRhodococcus equi [6]. Althoughwe are
aware that antimicrobial susceptibility testing is necessary for
appropriate treatment of infections, in vitro antimicrobial
susceptibilities of Rhodococcus equi are not standardized;
therefore, antibiotic choice is still essentially based on single-
center experience.
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